Sanna I.
- Country
- Finland
- Department
- Cancer Center
Research Overview
- Early Access Study of Zongertinib for the Treatment of Cancer in Patients Eligible for Anticancer Therapy
- A Randomized, Double-Blind Phase 2/3 Trial of Relatlimab and Nivolumab Versus Nivolumab Monotherapy in Untreated Metastatic or Unresectable Melanoma
- Evaluation of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab in Advanced Melanoma: A Randomized, Double-Blind, Phase 2/3 Study
Data & Insights
Has run more than one trial at 62 of 224 partner sites.
Specializations
Melanoma Research
The investigator specializes in treating advanced melanoma, with particular focus on developing innovative therapeutic approaches for previously untreated metastatic or unresectable cases.
- Combination Immunotherapy Strategies
- Novel Treatment Protocols
- First-line Therapy Development
Their research encompasses evaluating various therapeutic combinations to enhance treatment outcomes for melanoma patients.
Immunotherapy Development
The investigator focuses on advancing immunotherapy treatments, particularly examining the efficacy of targeted combinations including relatlimab and nivolumab for cancer treatment.
- Monotherapy vs Combination Approaches
- Treatment Response Assessment
- Progressive Disease Management
Their work involves evaluating therapeutic responses through progression-free survival metrics.
Advanced Cancer Studies
The investigator conducts research in targeted anti-cancer drug development, with emphasis on improving patient access to innovative therapeutic options.
- Disease Control Assessment
- Treatment Response Monitoring
- Patient Access Optimization
Their expertise includes evaluating disease control rates and treatment efficacy in advanced cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.